Millennium Pharmaceuticals ( MLNM) and its partner Johnson & Johnson ( JNJ) have started trials to examine the multiple myeloma drug Velcade as a possible treatment for nonsmall-cell lung cancer. The study will look at the safety and possible benefits of combining Velcade with the Eli Lilly ( LLY) drug Alimta in patients with advanced or spreading nonsmall-cell lung cancer. The companies plan to enroll 135 patients. Lung cancer is the leading cause of cancer-related deaths in both men and women, according to the National Institutes of Health, and the nonsmall-cell variety accounts for about 80% of all lung cancers. Velcade, which is already approved by the Food and Drug Administration to treat the blood cancer multiple myeloma, is also being studied to treat other lung cancers combined with Tarceva, a drug marketed by Genentech ( DNA) and OSI Pharmaceuticals ( OSIP). Millennium shares fell 13 cents to $10.37 Monday morning while J&J shares rose 8 cents to $57.55.